On the other hand, TNFα blockers can inhibit the expression of MUC4 and then overcome the resistance of primary trastuzumab in HER2-positive breast cancer, and may also be used as a potential new therapeutic target (18). The gene discussed is ERBB2; the disease is breast cancer.